Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Sigma-tau Research Switzerland S.a.

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Consiglio Nazionale Delle Ricerche

Alfasigma S.p.a.

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

Instituto Nazionale Per Lo Studio E La Cura Dei Tumori

Bristol Myers Squibb S.p.a.

Bristol-meyers Squibb S.p.a.

Giuseppe Giannini

Claudio Pisano

Sergio Penco

Loredana Vesci

Maria Ornella Tinti

Franco Zunino

Lucio Merlini

Sabrina Dallavalle

Mauro Marzi

Walter Cabri

Giangiacomo Torri

Benito Casu

Domenico Alloatti

Anna Maria Naggi

Gianfranco Battistuzzi

Federico Maria Arcamone

Carlo Scolastico

Paolo Lombardi

Fabio Animati

Maria Di Marzo

Alma Dal Pozzo

Paolo Carminati

Patrizia Minetti

Maurizio Taddei

Gian Piero Moretti

Teresa Riccioni

Edith Monteagudo

Mosé Santaniello

Tiziana Brunetti

Daniele Simoni

Nicola Fanto'

Ni Minghong

Ni Ming Hong

Marcella Marcellini

Enrico Garattini

Massimo Luigi Capobianco

Stefania Zanella

Maria Luisa Cervoni

Stefania Bonazzi

Anna Maria Garbesi

Riccardo Baruchello

Mosè Santaniello

Serena Ferrini

Davide Vignola

Riccardo Pezzi

Annamaria Naggi

Riccardo Barucchello

Ni Ming Hong Hong

The present invention relates to homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration, in which the resveratrol is solubilized in a solvent system consisting of omega-3 polyunsaturated fatty acids (n-3 PUFA), or their alkyl esters, and a ionic emulsifier. The composition according to the present invention can be formulated as food or nutritional supplement or medicament in the prevention or treatment of cardiovascular diseases due to lipid metabolism disorders and increased platelets aggregation, as well as damages due to free radicals and/or viral diseases.

Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration

The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical composition containing such compounds. 

Aryl triazole compounds with antitumoural activity

The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. 

Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments

The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumors, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis. 

Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties

The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds. 

Aryl isoxazole compounds with antitumoural activities

Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and Rgroups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.

Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Are described compounds of Formula (I) in which R, R', R&#x2033;, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.

Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities

Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) 

Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Indole derivatives of Formula (I+A) having antitumor and chemosensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumors. 

Indole derivatives having antitumor activity

Cinnamic and phenylpropiolic acid derivatives of formula (I) having antitumour and chemo sensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.

Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents

Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumor, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumors.

Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives

Compounds of Formula (I) are described in which the Rgroup is as defined in the specification and includes the condensation of the camptothecin molecule in position 7 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors &#x3b1;&#x3b2;and &#x3b1;&#x3b2;and with selective cytotoxic activity on human tumour cell lines at micromolar concentrations.

Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents

Compounds are disclosed with the general formula in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as medicaments for the treatment of tumors and viral and parasite infections.

7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups

Growing community of inventors

Pomezia, Italy

Giuseppe Giannini